Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
The DOI matches its Crossref record; 120 of the 121 references it cites were found in a registry or an index.
Abstract
The opposing actions of histone acetyltransferases (HATs) and histone deacetylases (HDACs) allow gene expression to be exquisitely regulated through chromatin remodelling. Aberrant transcription due to altered expression or mutation of genes that encode HATs, HDACs or their binding partners, is a key event in the onset and progression of cancer. HDAC inhibitors can reactivate gene expression and inhibit the growth and survival of tumour cells. The remarkable tumour specificity of these compounds, and their potency in vitro and in vivo, underscore the potential of HDAC inhibitors as exciting new agents for the treatment of cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Acetylation of the core histones of nucleosomes strongly influences gene transcription (Khochbin et al., 2001; Johnstone, 2002).”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Johnstone, 2002
In the citing paper
“Class I HDACs are ubiquitously expressed and are primarily located in the nucleus, while the class II enzymes can shuttle between the nucleus and cytoplasm and demonstrate tissue-specific expression (Johnstone, 2002; Marks et al., 2001; Vigushin and Coombes, 2002).”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Johnstone, 2002
In the citing paper
“Two related classes of eukaryotic zinc-containing HDACs have been recognized based upon sequence similarity: class I (HDAC1, 2, 3, and 8) and class II (HDAC4, 5, 6, 7, 9, and 10) (Johnstone, 2002; Gao et al., 2002).”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Johnstone, 2002
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Jenuwein, T., & Allis, C. D. (2001) · Science · doi:10.1126/science.1063127 · Cited by 9,756 · cited 1×
“In general terms, condensed chromatin mediates transcriptional repression, whereas transcriptionally active genes are in areas of open chromati”
BackgroundCrystal structure of the nucleosome core particle at 2.8 Å resolution
Luger, K., Mäder, A. W., Richmond, R. K., Sargent, D. F., & Richmond, T. J. (1997) · Nature · doi:10.1038/38444 · Cited by 9,466
Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase
Imai, S.-I., Armstrong, C. M., Kaeberlein, M., & Guarente, L. (2000) · Nature · doi:10.1038/35001622 · Cited by 3,510 · cited 1×
“pl?locus=sir2">Sir2 , a yeast transcriptional repressor that requires the cofactor NAD + for its deacetylase activit”
BackgroundhSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase
Vaziri, H., Dessain, S. K., Eaton, E. N., Imai, S.-I., Frye, R. A., Pandita, T. K., Guarente, L., & Weinberg, R. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00527-x · Cited by 2,659 · cited 3×
“Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of DAXX in acute promyelocytic leukaemia with t(15;17).”
Negative Control of p53 by Sir2α Promotes Cell Survival under Stress
Luo, J., Nikolaev, A. Y., Imai, S.-I., Chen, D., Su, F., Shiloh, A., Guarente, L., & Gu, W. (2001) · Cell · doi:10.1016/s0092-8674(01)00524-4 · Cited by 2,081
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
Gottlicher, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.6969 · Cited by 1,887 · cited 1×
“asp?DrugCode=1%2D1882&DrugName=VALPROIC+ACID+ORAL&DrugType=1">valproic acid , inhibit HDAC activity and affect the expression of numerous genes with disparate cellular function”
BackgroundHistone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866 · cited 1×
“gov/cancer_information/cancer_type/leukemia/">leukaemias and solid tumours to express differentiated characteristics and stop proliferatin”
BackgroundCameron, E. E., Bachman, K. E., Myöhänen, S., Herman, J. G., & Baylin, S. B. (1999) · Nature Genetics · doi:10.1038/5047 · Cited by 1,857
Acetylation of Histones and Transcription-Related Factors
Sterner, D. E., & Berger, S. L. (2000) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.64.2.435-459.2000 · Cited by 1,780 · cited 5×
“Mechanisms of transcriptional repression by the t(8;21)-, t(12;21)-, and inv(16)-encoded fusion proteins.”
BackgroundInfluential
Research works printed but not linked: 1
- Ruefli, A. A. Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-gp expressing cells. Int. J. Cancer. (in the press).
Cited by
Items 601–700 of 1,001
Cai, J., Wei, H., Hong, K. H., Wu, X., Zong, X., Cao, M., Wang, P., Li, L., Sun, C., Chen, B., et al. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.04.028 · Cited by 45
Calonghi, N., Cappadone, C., Pagnotta, E., Boga, C., Bertucci, C., Fiori, J., Tasco, G., Casadio, R., & Masotti, L. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m400424-jlr200 · Cited by 51
“The remarkable tumor specificity of these compounds, and their potency in vitro and in vivo, underscore the potential of HDAC inhibitors as exciting new agents for the treatment of cancer (10, 11).”
Mining the Epigenome for Methylated Genes in Lung Cancer
Tessema, M., & Belinsky, S. A. (2008) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200805-045th · Cited by 44
“Histone H3 is a common target for deacetylation, and this process has been strongly linked to maintaining compacted nucleosomes to block transcription ( 25 ).”
BackgroundAbramczyk, H., Surmacki, J. M., Kopeć, M., Olejnik, A. K., Kaufman‐Szymczyk, A., & Fabianowska‐Majewska, K. (2016) · The Analyst · doi:10.1039/c6an00859c · Cited by 44
Okada, Y., Numata, T., Sato-Numata, K., Sabirov, R. Z., Liu, H., Mori, S., & Morishima, S. (2019) · Current topics in membranes · doi:10.1016/bs.ctm.2019.03.001 · Cited by 46
KDELR2 promotes breast cancer proliferation via HDAC3‐mediated cell cycle progression
Wei, H., Ma, W., Lü, X., Liu, H., Lin, K., Wang, Y., Ye, Z., Sun, L., Huang, Z.-T., Pan, T., et al. (2021) · 癌症:英文版 · doi:10.1002/cac2.12180 · Cited by 46
“Food and Drug Administration as anticancer agents because of their remarkable effects on inducing cell cycle arrest, apoptosis, and differentiation in cancer cells [5, 6].”
BackgroundA Diamond Nanoneedle Array for Potential High‐Throughput Intracellular Delivery
Chen, X., Zhu, G., Yang, Y., Wang, B., Yan, L., Zhang, K. Y., Lo, K. K., & Zhang, W. (2013) · Advanced Healthcare Materials · doi:10.1002/adhm.201200362 · Cited by 44
FE65 Binds Teashirt, Inhibiting Expression of the Primate-Specific Caspase-4
Kajiwara, Y., Akram, A. M., Katsel, P., Haroutunian, V. H., Schmeidler, J., Beecham, G. W., Haines, J. L., Pericak‐Vance, M. A., & Buxbaum, J. D. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005071 · Cited by 51
“In mammals, there are 18 HDACs identified to date and they are assigned into three classes based on the structural similarity to yeast homologues [20,21].”
BackgroundRyu, J. K., Lee, W. J., Lee, K. H., Hwang, J., Kim, Y., Yoon, Y. B., & Kim, C. Y. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.05.040 · Cited by 48
“HDAC inhibitors have been shown to exert various anti-tumor effects, such as growth inhibition, the induction of apoptosis or differentiation, and the blocking of angiogenesis in vivo [2,3].”
BackgroundEnhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition
Chinnaiyan, P., Varambally, S., Tomlins, S. A., Ray, S. S., Huang, S., Chinnaiyan, A. M., & Harari, P. M. (2005) · International Journal of Cancer · doi:10.1002/ijc.21465 · Cited by 47
“nature of epigenetic transcriptional control where DNA and histone methylation provide a dominant-repressive effect over histone acetylation.(11) Despite mechanistic uncertainty, genes reported to be affected by HDAC inhibition influence a variety of oncogenic processes including cell cycle progression, proliferation,…”
BackgroundHDAC7 Inhibits Osteoclastogenesis by Reversing RANKL-Triggered β-Catenin Switch
Jin, Z., Wei, W., Dechow, P. C., & Wan, Y. (2012) · Molecular Endocrinology · doi:10.1210/me.2012-1302 · Cited by 44
“Numerous HDAC inhibitors are currently in clinical trials for the treatment of a bevy of diseases including cancer and neurodegeneration (25, 26).”
BackgroundDu, L., Musson, D. G., & Wang, A. Q. (2005) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.1984 · Cited by 44
New side chain design for pH-responsive block copolymers for drug delivery
Ray, P., Kale, N. R., & Quadir, M. (2021) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2021.111563 · Cited by 46
Curriculum vitae of HDAC6 in solid tumors
Zheng, Y., Kang, H., Wang, B., Zhu, Y.-Z., Mamun, M., Zhao, L., Nie, H., Liu, Y., Zhao, L., Zhang, X., et al. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.123219 · Cited by 43
Uciechowska, U., Schemies, J., Scharfe, M., Lawson, M. K., Wichapong, K., Jung, M., & Sippl, W. (2011) · MedChemComm · doi:10.1039/c1md00214g · Cited by 43
Lohse, B., Nielsen, A. L., Kristensen, J. B. L., Helgstrand, C., Cloos, P. A., Olsen, L., Gajhede, M., Clausen, R. P., & Kristensen, J. L. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201101849 · Cited by 48
Spratlin, J. L., Pitts, T. M., Kulikowski, G. N., Morelli, M. P., Tentler, J. J., Serkova, N. J., & Eckhardt, S. G. (2011) · PubMed · Cited by 46
Dong, J., Zheng, N., Wang, X., Tang, C. C., Yan, P., Zhou, H., & Huang, J. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.03.026 · Cited by 43
“Ricky reported (Johnstone, 2002) that tumor cells undergo G2/M checkpoint, then replicated DNA and hyperacetylated histones accumulate which lead to the sensitivity of tumor cells, and subsequently tumor cells undergo apoptosis.”
BackgroundDomenech, J. M. D., Pippa, R., Tápia, M., Gascón, P., Bachs, O., & Bosch, M. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9837-8 · Cited by 46
“Previous studies support the fact that HDACi induced, to a variable extent, cell cycle arrest, differentiation and/or apoptosis in preclinical in vitro and in vivo models [4].”
BackgroundCuneo, K. C., Fu, A., Osusky, K. L., Huamani, J., Hallahan, D. E., & Geng, L. (2007) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3280b10d57 · Cited by 48
Su, X., Ren, C., & Freitas, M. A. (2007) · Expert Review of Proteomics · doi:10.1586/14789450.4.2.211 · Cited by 47
Vinodhkumar, R., Song, Y., & Devaki, T. (2007) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2007.06.002 · Cited by 49
Bauer, S., & Joensuu, H. (2015) · Drugs · doi:10.1007/s40265-015-0440-8 · Cited by 43
“HDACIs have selectivity for cell cycle inhibitory genes [75].”
BackgroundMechanisms of Selective Anticancer Action of Histone Deacetylase Inhibitors
Insinga, A., Minucci, S., & Pelicci, P. G. (2005) · Cell Cycle · doi:10.4161/cc.4.6.1717 · Cited by 47
Huang, W., Chen, C., Chao, S.-W., Lee, S., Hsu, F., Lu, Y., Hung, M., & Chang, C. (2010) · ChemMedChem · doi:10.1002/cmdc.200900494 · Cited by 42
Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer
Eskander, R. N., & Tewari, K. S. (2014) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2014.25.3.249 · Cited by 42
“HDACs remove the acetyl groups, returning an overall positive charge, which is thought to inhibit transcription of tumor suppressor genes in various malignancies [39-41].”
BackgroundGrassadonia, A., Cioffi, P., Simiele, F., Iezzi, L., Zilli, M., & Natoli, C. (2013) · Cancers · doi:10.3390/cancers5030919 · Cited by 48
“to confer a survival advantage to cancer cells by regulating the expression of genes involved in growth, differentiation and apoptosis [23].”
BackgroundPyridylalanine‐Containing Hydroxamic Acids as Selective HDAC6 Inhibitors
Schäfer, S., Saunders, L., Schlimme, S., Valkov, V., Wagner, J. M., Kratz, F., Sippl, W., Verdin, E., & Jung, M. (2009) · ChemMedChem · doi:10.1002/cmdc.200800196 · Cited by 41
Cho, H. J., Kim, S. Y., Kim, K. H., Kang, W. K., kim, J. I., Oh, S. T., Kim, J. S., & An, C. H. (2009) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-7-49 · Cited by 43
“Oncogenesis is related to inactivation of histone acetyltransferase, and it is thought that hyperactivation of HDAC suppresses the transcription of tumor suppressor genes, therefore playing an important part in carcinogenesis [16].”
BackgroundBrożek-Płuska, B., Kopeć, M., & Abramczyk, H. (2016) · Analytical Methods · doi:10.1039/c6ay02559e · Cited by 42
Xie, R., Li, Y., Tang, P., & Yuan, Q. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.08.041 · Cited by 43
Noro, R., Miyanaga, A., Minegishi, Y., Okano, T., Seike, M., Soeno, C., Kataoka, K., Matsuda, K., Yoshimura, A., & Gemma, A. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01559.x · Cited by 44
Syntheses of Amamistatin Fragments and Determination of Their HDAC and Antitumor Activity
Fennell, K. A., & Miller, M. J. (2007) · Organic Letters · doi:10.1021/ol070382e · Cited by 43
In vivo haematopoietic activity is induced in neurosphere cells by chromatin‐modifying agents
Schmittwolf, C., Kirchhof, N., Jauch, A. S., Dürr, M., Harder, F., Zenke, M., & Müller, A. M. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600546 · Cited by 46
“In our experiments, we utilized neurosphere cells from wildtype (wt) and from bcl2-transgenic embryonic day (E) 14.5 embryos (Figure 1A), with expression of the latter gene as protection against the apoptosis-inducing activities of TSA (Koyama et al, 2000; Johnstone, 2002).”
BackgroundMethodInfluentialLysophosphatidic acid acyltransferase-?: a novel target for induction of tumour cell apoptosis
Bonham, L., Leung, D. W., White, T., Hollenback, D., Klein, P., Tulinsky, J., Coon, M. E., de Vries, P., & Singer, J. W. (2003) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.7.5.643 · Cited by 42
“These include inhibition of histone deacetylases [19] to allow increased transcription of differentiation genes, proteosome inhibition to decrease NF-κB [20], or targeting the antiapoptotic factors such as bcl-2, survivin [21], raf [22] or telomerase.”
BackgroundLi, X., Tu, Z., Li, H., Liu, C., Li, Z., Sun, Q., Yao, Y., Liu, J., & Jiang, S. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300371t · Cited by 43
Gamal‐Eldeen, A. M., El‐Daly, S. M., Borai, I. H., Wafay, H. A., & Abdel-Ghaffar, A.-R. B. (2013) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2013.03.013 · Cited by 45
Karagiannis, T. C., & El‐Osta, A. (2006) · Epigenetics · doi:10.4161/epi.1.3.3328 · Cited by 46
Chen, L., Petrelli, R., Gao, G. Y., Wilson, D. J., McLean, G. T., Jayaram, H. N., Sham, Y. Y., & Pankiewicz, K. W. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.06.081 · Cited by 43
Markus, M. A., Marques, F. Z., & Morris, B. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028926 · Cited by 45
“increasing number of substances, including natural ones such as caffeine, that have been found to be able to modulate alternative splicing [9,10,11], toxicity of some and lack of specificity of others remain major caveats.”
BackgroundAntitumor Action of a Novel Histone Deacetylase Inhibitor, YF479, in Breast Cancer
Zhang, T., Chen, Y., Li, J., Yang, F., Wu, H., Dai, F., Hu, M., Lü, X., Peng, Y., Liu, M., et al. (2014) · Neoplasia · doi:10.1016/j.neo.2014.07.009 · Cited by 44
“Aberrant HDAC activity is proposed to be the key event in tumor formation, since excessive HDAC activity inappropriately repressed transcription of tumor suppressor genes [6].”
BackgroundDual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release
Daniel, K. B., Sullivan, E. D., Chen, Y., Chan, J. C., Jennings, P. A., Fierke, C. A., & Cohen, S. M. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00539 · Cited by 47
Wang, Y. F., Liu, F., Sherwin, S. K., Farrelly, M. L., Yan, X. G., Croft, A. J., Liu, T., Jin, L., Zhang, X. D., & Jiang, C. C. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.11.009 · Cited by 42
Ediriweera, M. K., & Cho, S. K. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107437 · Cited by 44
Favero, C., Carriazo, S. M., Cuarental, L., Fernández-Prado, R., Gomá-Garcés, E., Pérez-Gómez, M. V., Ortíz, A., Fernández‐Fernández, B., & Sánchez-Niño, M. D. (2021) · Nutrients · doi:10.3390/nu13041273 · Cited by 47
“Additionally, butyrate modulates the epigenetic regulation of gene expression by inhibiting histone deacetylase (HDAC) with resulting anti-cancer and anti-inflammatory properties [58,61,62].”
BackgroundMolecular mechanisms of histone deacetylases and inhibitors in renal fibrosis progression
Wang, J., Li, J., Zhang, X., Zhang, M., Hu, X., & Yin, H. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.986405 · Cited by 42
“Johnstone (2002) proposed that HDACi could inhibit the G2 to M cell cycle transition in tumor cells and induce a high expression of major histocompatibility complex (MHC) class I and II molecules, Intercellular Adhesion Molecule 1 (ICAM 1), and activating factor (CD40) in tumor cells, thereby…”
BackgroundKinugasa, F., Noto, T., Matsuoka, H., Urano, Y., Sudo, Y., Takakura, S., & Mutoh, S. (2010) · Transplant Immunology · doi:10.1016/j.trim.2010.02.003 · Cited by 43
Muscal, J. A., Scorsone, K. A., Zhang, L., Ecsedy, J., & Berg, S. L. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9831-9 · Cited by 44
“HDAC inhibitors induce cell differentiation, cell cycle arrest, and apoptosis, and inhibit migration, invasion and angiogenesis in many cancer models [2, 3].”
Ragno, R., Simeoni, S., Rotili, D., Caroli, A., Botta, G., Brosch, G., Massa, S., & Mai, A. (2007) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2007.05.004 · Cited by 45
Wang, C., Flemming, C. J., & Cheng, Y. (2012) · MedChemComm · doi:10.1039/c2md20024d · Cited by 43
QSAR Studies of PC-3 cell line inhibition activity of TSA and SAHA-like hydroxamic acids
Wang, D., Wiest, O., Helquist, P. M., Lan-Hargest, H.-Y., & Wiech, N. L. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.11.062 · Cited by 43
Sonnemann, J., Hartwig, M., Plath, A., Kumar, K. S., Müller, C., & Beck, J. F. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.02.009 · Cited by 41
“DNA, while DNA fragmentation would not be an obligatory prerequisite for cell death [2].”
BackgroundRecent progress in the development of assays suited for histone deacetylase inhibitor screening
Wegener, D., Hildmann, C., & Schwienhorst, A. (2003) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2003.08.008 · Cited by 45
Henderson, C. J., & Brancolini, C. (2003) · Drug Resistance Updates · doi:10.1016/s1368-7646(03)00067-0 · Cited by 54
“Representative examples of the HDIs are shown in Table 1 and include short-chain fatty acids, hydroxamic acids, epoxyketone-containing cyclic tetrapeptides, non-epoxyketone-containing cyclic tetrapeptides, and benzamides (Marks et al., 2000, 2001b; Johnstone, 2002; Saito et al., 1999; Suzuki et al., 1999; Prakash et a…”
BackgroundInfluentialA phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors
Dickson, M. A., Rathkopf, D. E., Carvajal, R. D., Grant, S., Roberts, J. D., Reid, J. M., Ames, M. M., McGovern, R. M., Lefkowitz, R. A., Gönen, M., et al. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9447-x · Cited by 46
Kulka, L. A. M., Fangmann, P.-V., Panfilova, D., & Olzscha, H. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00425 · Cited by 44
“However, a larger study should be executed in order to make a valid statement, thereby also concentrating on cyclin D1 (CCND1), as it is known to be commonly down-regulated by various HDACi (Johnstone, 2002).”
BackgroundThiruvengadam, M., Subramanian, U., Venkidasamy, B., Thirupathi, P., Samynathan, R., Shariati, M. A., Ребезов, М. Б., Chung, I., & Rengasamy, K. R. R. (2021) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2021.1954874 · Cited by 42
Identification of type-specific anticancer histone deacetylase inhibitors: road to success
Noureen, N., Rashid, H., & Kalsoom, S. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1324-y · Cited by 43
“Because of their short side chains, short-chain fatty acids have low potency, which limits their contact with the catalytic pocket of HDACs [77].”
BackgroundKanao, K., Mikami, S., Mizuno, R., Shinojima, T., Murai, M., & Oya, M. (2008) · The Journal of Urology · doi:10.1016/j.juro.2008.04.136 · Cited by 41
Chromatin Modifying Agents in theIn VitroProduction of Bovine Embryos
Monteiro, F. M., Oliveira, C. S., Oliveira, L. Z., Saraiva, N. Z., Mercadante, M. E. Z., Lopes, F. L., Arnold, D. R., & Garcia, J. M. (2010) · Veterinary Medicine International · doi:10.4061/2011/694817 · Cited by 45
“Among the known inhibitors, some of the most used are (I) trichostatin A, (II) valproic acid, clinically used in the treatment of epilepsy, and (III) sodium butyrate [84].”
Peltonen, K., Kiviharju, T. M., Järvinen, P. M., Ra, R., & Laiho, M. (2005) · Pigment Cell Research · doi:10.1111/j.1600-0749.2005.00225.x · Cited by 51
Krunic, D., Moshir, S., Greulich-Bode, K. M., Figueroa, R., Cerezo, A., Stammer, H., Stark, H.-J., Gray, S. G., Nielsen, K. V., Hartschuh, W., et al. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.02.005 · Cited by 40
“Therefore, we treated the keratinocytes in monolayer cultures with the histone deacetylase inhibitor FK228 (now known as romidepsin) (for reviews see [33,34]) and measured TRAP activity after 3, 6, 12, and 24 h.”
MethodZhou, H., Wang, C., Ye, J., Chen, H., & Tao, R. N. (2017) · Gene · doi:10.1016/j.gene.2017.09.034 · Cited by 40
Routholla, G., Pulya, S., Patel, T., Abdul Amin, S., Adhikari, N., Biswas, S., Jha, T., & Ghosh, B. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105050 · Cited by 39
Qi, X., Li, Y., Fang, C., Jia, Y., Chen, M., Chen, X., & Jia, J. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1242115 · Cited by 49
Nam, N., Huong, T. L., Dung, D. T. M., Dung, P. T. P., Oanh, D. T. K., Park, S. H., Kim, K., Han, B. W., Yun, J., Kang, J. S., et al. (2013) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2013.832238 · Cited by 39
Potent and Orally Efficacious Bisthiazole-Based Histone Deacetylase Inhibitors
Chen, F., Chai, H., Su, M., Zhang, Y., Li, J. X., Xie, X., & Nan, F. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400470s · Cited by 42
Rahman, R., Osteso-Ibáñez, T., Hirst, R. A., Levesley, J., Kilday, J., Quinn, S., Peet, A. C., O’Callaghan, C., Coyle, B., & Grundy, R. G. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0272 · Cited by 40
“toxicity against tumor cells compared to untransformed cells (33, 34).”
Wong, N.-S., Seah, E., Wang, L., Yeo, W.-L., Yap, H., Chuah, B., Lim, Y.-W., Ang, P., Tai, B., Lim, R., et al. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32834a8639 · Cited by 40
LTR12 promoter activation in a broad range of human tumor cells by HDAC inhibition
Krönung, S. K., Beyer, U., Chiaramonte, M. L., Dolfini, D., Mantovani, R., & Dobbelstein, M. (2016) · Oncotarget · doi:10.18632/oncotarget.9255 · Cited by 45
“While acetylation of histones by HATs is believed to mostly relax the chromatin and render it more accessible to the transcription machinery, deacetylation opposes these effects [33, 34].”
BackgroundLv, W., Zhang, G., Bařinka, C., Eubanks, J. H., & Kozikowski, A. P. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00012 · Cited by 39
Uba, A. İ., & Yelekçi, K. (2017) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2017.1384402 · Cited by 43
“These cells subsequently die via apoptotic, autophagic or reactive oxygen species (ROS)-mediated pathways (Bolden, Peart, & Johnstone, 2006; Johnstone, 2002; Lane & Chabner, 2009; Minucci & Pelicci, 2006; Monneret, 2005; Xu, Parmigiani, & Marks, 2007).”
Singh, A., Chang, T.-Y., Kaur, N., Hsu, K., Yen, Y., Lin, T. E., Lai, M.-J., Lee, S., & Liou, J. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113169 · Cited by 39
Hertel, J., Heinken, A., Martinelli, F., & Thiele, I. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1915673 · Cited by 44
Dietrich, C. S., Greenberg, V. L., DeSimone, C. P., Modesitt, S. C., van Nagell, J. R., Craven, R. J., & Zimmer, S. G. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.09.039 · Cited by 48
“Histone deacetylase inhibitors (HDACI) are gaining attention as anti-neoplastic agents as they induce cell differentiation, cell cycle arrest, and apoptosis [6–12].”
BackgroundShindoh, N., Mori, M., Terada, Y., Oda, K., Amino, N., Kita, A., Taniguchi, M., Sohda, K., Nagai, K., Sowa, Y., et al. (2008) · International Journal of Oncology · doi:10.3892/ijo.32.3.545 · Cited by 41
“Abnormal recruitment of HDACs by mutant transcription factors formed by chromosomal translocation also occurs in various leukemias (6).”
BackgroundTrithiocarbonates—Exploration of a new head group for HDAC inhibitors
Dehmel, F., Ciossek, T., Maier, T. M., Weinbrenner, S., Schmidt, B. G., Zoche, M., & Beckers, T. L. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.06.063 · Cited by 46
Hsieh, C.-L., Wang, H.-E., Tsai, W., Peng, C.-C., & Peng, R. Y. (2011) · Toxicology · doi:10.1016/j.tox.2011.10.015 · Cited by 39
Taha, T. Y., Aboukhatwa, S. M., Knopp, R. C., Ikegaki, N., Abdelkarim, H., Neerasa, J., Lu, Y., Neelarapu, R., Hanigan, T. W., Thatcher, G. R. J., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00126 · Cited by 38
Castro-Galache, M. D., Ferragut, J. A., Barberá, V. M., Martín‐Orozco, E., González-Ros, J. M., García-Morales, P., & Saceda, M. (2003) · International Journal of Cancer · doi:10.1002/ijc.10998 · Cited by 40
Dai, B., Wang, F., Wang, Y., Zhu, J., Li, Y., Zhang, T., Zhao, L., Wang, L., Gao, W., Li, J., et al. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01139-8 · Cited by 43
“Histone deacetylases (HDACs) are an important class of epigenetic enzymes that regulate gene expression by modulating acetylation modification [12].”
BackgroundCao, Q., Yu, C., Xue, R., Hsueh, W., Pan, P., Chen, Z., Wang, S., McNutt, M. A., & Gu, J. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.07.020 · Cited by 39
Targeted therapy in acute myeloid leukaemia: current status and future directions
Stapnes, C., Gjertsen, B. T., Reikvam, H., & Bruserud, Ø. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/14728220902787628 · Cited by 43
“Only a small part of the genome is affected by changes in chromatin structure by acetylation of histones [27].”
BackgroundImpairment of p53 acetylation by EWS-Fli1 chimeric protein in Ewing Family Tumors
Li, Y., Li, X., Fan, G.-Y., Fukushi, J., Matsumoto, Y., Iwamoto, Y., & Zhu, Y. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.01.018 · Cited by 46
Helland, Ø., Popa, M. L., Bischof, K., Gjertsen, B. T., McCormack, E., & Bjørge, L. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158208 · Cited by 40
“Panobinostat has also demonstrated effective HDAC inhibition in breast, prostate, colon and pancreatic cell lines, while its effects on normal cells were marginal [12, 25].”
BackgroundGut microbiota promotes production of aromatic metabolites through degradation of barley leaf fiber
Li, D., Wang, P., Wang, P., Hu, X., & Chen, F. (2018) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2018.05.001 · Cited by 40
Hanif, M., Arshad, J. Z., Astin, J. W., Rana, Z., Zafar, A., Movassaghi, S., Leung, E. Y., Patel, K. D., Söhnel, T., Reynisson, J., et al. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202005758 · Cited by 42
Insights Into the Function and Clinical Application of HDAC5 in Cancer Management
Yang, J., Gong, C., Ke, Q., Fang, Z., Chen, X., Ye, M., & Xi Tao, X. U. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.661620 · Cited by 48
“The former domain, which is also referred to as the HDAC domain, contains a nuclear export sequence(NES) and is highly conserved (80% homology) across class IIa HDACs; it is composed of 400-450 amino acids and shares 53% sequence similarity with yeast hda1 (15).”
BackgroundAli, A. I., Wang, M., von Scheidt, B., Domínguez, P. M., Harrison, A. J., Tantalo, D. G. M., Kang, J., Oliver, A. J., Chan, J. D., Du, X., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1141 · Cited by 44
“Farydak, Novartis Pharmaceuticals) is considered a highly effective inhibitor of most HDAC enzymes with limited toxicity (7, 8) and was approved by the FDA for the treatment of multiple myeloma (6).”
BackgroundSelf-citationAdeshakin, A. O., Adeshakin, F. O., Yan, D., & Wan, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.781660 · Cited by 43
Emerging and investigational therapies for neuroblastoma
Applebaum, M. A., Desai, A. V., Bender, J. G., & Cohn, S. L. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2017.1304212 · Cited by 39
“Decreased histone acetylation has long been a hallmark of cancer, altering chromatin structure and modifying transcriptional pathways [86].”
BackgroundDai, Y., Rahmani, M., & Grant, S. (2003) · Cell Cycle · doi:10.4161/cc.2.5.465 · Cited by 43
Lactate and lysine lactylation of histone regulate transcription in cancer
Yang, Y., Luo, N., Gong, Z., Zhou, W., Ku, Y., & Chen, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e38426 · Cited by 45
Sun, W., Zhou, X., Zheng, J., Lu, M., Nie, J.-Y., Yang, X., & Zheng, Z. (2012) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmr113 · Cited by 42
Cancer Chemoradiotherapy Duo: Nano-Enabled Targeting of DNA Lesion Formation and DNA Damage Response
Jiang, W., Li, Q., Zhu, Z., Wang, Q., Dou, J., Zhao, Y., Lv, W., Zhong, F., Yao, Y., Zhang, G., et al. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b10901 · Cited by 37
Xu, N., Ding, T., Liu, Y., Zheng, W., Liu, Q., Yin, Z., Xiang, X., Xu, D., Mai, K., & Ai, Q. (2020) · Aquaculture Nutrition · doi:10.1111/anu.13192 · Cited by 41
Evolution of wound-activated regeneration pathways in the plant kingdom
Liang, Y., Heyman, J., Lu, R., & Veylder, L. D. (2023) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2023.151291 · Cited by 37
Kim, W.-J., Lee, J.-W., Quan, C., Youn, H.-J., Kim, H.-M., & Bae, S.-C. (2011) · Journal of Urology · doi:10.1016/j.juro.2011.02.017 · Cited by 37
Valproic acid as a therapeutic agent for head and neck squamous cell carcinomas
Erlich, R. B., Rickwood, D., Coman, W. B., Saunders, N. A., & Guminski, A. D. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0747-1 · Cited by 40
“most solid tumours the primary eVect of VA is a reversible cytostatic response [22].”
BackgroundA fluorescent histone deacetylase (HDAC) inhibitor for cellular imaging
Fleming, C. L., Ashton, T. D., Nowell, C. J., Devlin, M. G., Natoli, A. L., Schreuders, J., & Pfeffer, F. M. (2015) · Chemical Communications · doi:10.1039/c5cc02059j · Cited by 40
Metadata
- Authors
- Johnstone, R. W.
- Affiliations
- Peter MacCallum Cancer Centre (AU)
- Corresponding author
- Johnstone, Ricky W.
- ORCID
- Johnstone, Ricky W.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2002-04
- Volume
- 1
- Issue
- 4
- Pages
- 287-299
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1971621147
- Cited by
- 1,515
- References
- 121
- Citations by year
- 2026: 9 · 2025: 21 · 2024: 23 · 2023: 46 · 2022: 35 · 2021: 59 · 2020: 50 · 2019: 55 · 2018: 38 · 2017: 65 · 2016: 50 · 2015: 64 · 2014: 54 · 2013: 81 · 2012: 94
- FWCI
- 5.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- National Health and Medical Research Council
- National Medical Research Council
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- histone deacetylase inhibitors, histone acetyltransferase, chromatin remodeling, gene expression regulation, aberrant transcription, tumor cell growth inhibition, cancer therapy
- MeSH terms
- Acetylation, Animals, Antineoplastic Agents, Cell Differentiation, Chromatin, Clinical Trials as Topic, Enzyme Inhibitors, Histones, Humans, Neoplasms, Gene Expression Regulation, Neoplastic, Apoptosis, DNA Methylation, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.